This report provides the current prevalent population for schizophrenia across 27 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Finland, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Schizophrenia is a mental illness characterised by psychosis, apathy and withdrawal, as well as cognitive impairment. It usually develops between late adolescence and young adult age and although no significant differences in the prevalence of schizophrenia have been observed between men and women overall, there are differences in age at onset and tendency to present certain symptoms. Schizophrenia constitutes a significant burden to social and professional life, with more severe forms also causing basic self-care problems. With its life-long duration, it is one of the leading causes of long-term disability worldwide.
Providing a value-added level of insight from the analysis team, the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of schizophrenia include:
Cardiopulmonary, metabolic, gastrointestinal and malignant diseases
Abuse of psychoactive substances
Adverse effects of antipsychotics
Reason to buy
Ability to quantify patient populations in global schizophrenia market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of schizophrenia and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Better understanding of the impact of specific co-morbid conditions on the prevalent population of schizophrenia patients.
Identification of schizophrenia patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of schizophrenia patients.
Key Topics Covered:
Cause Of The Disease
Risk Factors & Prevention
Diagnosis Of The Disease
Variation By Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid Conditions / Features Associated With The Disease